AKT1 Antibody (monoclonal) (M03)
Mouse monoclonal antibody raised against a full length recombinant AKT1.
|Application ||WB, IHC, IF, IP|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||55686 Da|
|Other Names||RAC-alpha serine/threonine-protein kinase, Protein kinase B, PKB, Protein kinase B alpha, PKB alpha, Proto-oncogene c-Akt, RAC-PK-alpha, AKT1, PKB, RAC|
|Target/Specificity||AKT1 (AAH00479.1, 1 a.a. ~ 480 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||AKT1 Antibody (monoclonal) (M03) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene.
HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Izquierdo L, et al. Anticancer Res, 2010 Jun. PMID 20651405.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Lin RJ, et al. Mol Carcinog, 2010 Aug. PMID 20623644.Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Slattery ML, et al. Carcinogenesis, 2010 Sep. PMID 20622004.The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer. Benesch C, et al. Anticancer Res, 2010 May. PMID 20592362.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.